Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients

Journal of Clinical Lipidology

Volumn 10, Issue 3, 2016, Pages 519-527.e4

  Nicholls, Stephen J ^a   Ruotolo, Giacomo ^b   Brewer, H Bryan ^c   Wang, Ming Dauh ^b   Liu, Liping ^b   Willey, Mark B ^b   Deeg, Mark A ^b   Krueger, Kathryn A ^b   Nissen, Steven E ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ELI LILLY AND COMPANY   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CETP inhibitor; Evacetrapib; Hypercholesterolemia; LDL particle; Lipoprotein(a); Small LDL

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN; BENZODIAZEPINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CHEMISTRY; DRUG INTERACTION; MIDDLE AGED; PARTICLE SIZE;

BENZODIAZEPINES; CHOLESTEROL, LDL; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); MALE; MIDDLE AGED; PARTICLE SIZE;

EID: 84971280903     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.11.014     Document Type: Article

References (42)

1. C. Baigent, A. Keech, P.M. Kearney, and et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
2. C. Baigent, L. Blackwell, J. Emberson, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. C.P. Cannon, M.A. Blazing, R.P. Giugliano, and et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes N Engl J Med 372 2015 2387 2397
4. S.M. Boekholdt, B.J. Arsenault, S. Mora, and et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
5. G.J. Blake, J.D. Otvos, N. Rifai, and P.M. Ridker Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women Circulation 106 2002 1930 1937
6. K. El Harchaoui, W.A. van der Steeg, E.S. Stroes, and et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study J Am Coll Cardiol 49 2007 547 553
7. C.D. Gardner, S.P. Fortmann, and R.M. Krauss Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women JAMA 276 1996 875 881
8. R.M. Krauss All low-density lipoprotein particles are not created equal Arterioscler Thromb Vasc Biol 34 2014 959 961
9. S. Mora, J.D. Otvos, N. Rifai, R.S. Rosenson, J.E. Buring, and P.M. Ridker Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 2009 931 939
10. B.T. Steffen, W. Guan, A.T. Remaley, and et al. Use of lipoprotein particle measures for assessing coronary heart disease risk post-American Heart Association/American College of Cardiology guidelines: the Multi-Ethnic Study of Atherosclerosis Arterioscler Thromb Vasc Biol 35 2015 448 454
11. S. Parish, A. Offer, R. Clarke, and et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study Circulation 125 2012 2469 2478
12. R.C. Hoogeveen, J.W. Gaubatz, W. Sun, and et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study Arterioscler Thromb Vasc Biol 34 2014 1069 1077
13. B.G. Nordestgaard, M.J. Chapman, K. Ray, and et al. Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
14. C.P. Cannon, S. Shah, H.M. Dansky, and et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
15. G.K. Hovingh, J.J. Kastelein, S.J. van Deventer, and et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial Lancet 386 2015 452 460
16. S.J. Nicholls, H.B. Brewer, J.J. Kastelein, and et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
17. K.K. Ray, and A.J. Vallejo-Vaz The evolving role of CETP inhibition: beyond HDL cholesterol Lancet 386 2015 412 414
18. E.J. Jeyarajah, W.C. Cromwell, and J.D. Otvos Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy Clin Lab Med 26 2006 847 870
19. H.H. Schmidt, J.C. Genschel, S. Wagner, and M.P. Manns Quantification of lipoprotein(a): comparison of an automated latex-enhanced nephelometric assay with an immunoenzymometric method Eur J Clin Chem Clin Biochem 34 1996 119 124
20. O.N. Keene The log transformation is special Stat Med 14 1995 811 819
21. D. Gaudet, D.J. Kereiakes, J.M. McKenney, and et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials) Am J Cardiol 114 2014 711 715
22. R.D. Santos, F.J. Raal, A.L. Catapano, J.L. Witztum, E. Steinhagen-Thiessen, and S. Tsimikas Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials Arterioscler Thromb Vasc Biol 35 2015 689 699
23. M.B. Boffa, and M.L. Koschinsky Screening for and management of elevated Lp(a) Curr Cardiol Rep 15 2013 417
24. T.A. Thomas, H. Zhou, T. Roddy, and et al. Mechanisms by which anacetrapib lowers plasma Lipoprotein (a) concentration Arterioscler Thromb Vasc Biol 32 5 Suppl 2012 A329 Abstract
25. W.E. Boden, J.L. Probstfield, T. Anderson, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
26. M.J. Landray, R. Haynes, J.C. Hopewell, and et al. Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
27. R.M. Krauss, C.A. Pinto, Y. Liu, A.O. Johnson-Levonas, and H.M. Dansky Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin J Clin Lipidol 9 2015 93 102
28. R.M. Krauss, K. Wojnooski, J. Orr, and et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib J Lipid Res 53 2012 540 547
29. S. Yamashita, Y. Matsuzawa, M. Okazaki, and et al. Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity Atherosclerosis 70 1988 7 12
30. P.T. Williams, X.Q. Zhao, S.M. Marcovina, J.D. Otvos, B.G. Brown, and R.M. Krauss Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease Atherosclerosis 233 2014 713 720
31. M.P. Caulfield, S. Li, G. Lee, and et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis Clin Chem 54 2008 1307 1316
32. M.H. Davidson, J.M. McKenney, C.L. Shear, and J.H. Revkin Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels J Am Coll Cardiol 48 2006 1774 1781
33. J.M. McKenney, M.H. Davidson, C.L. Shear, and J.H. Revkin Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin J Am Coll Cardiol 48 2006 1782 1790
34. J.S. Millar, G. Reyes-Soffer, P. Jumes, and et al. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects J Clin Invest 125 2015 2510 2522
35. S.J. Nicholls, G. Ruotolo, H.B. Brewer, and et al. Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib J Am Coll Cardiol 66 2015 2201 2210
36. A.V. Khera, M. Cuchel, M. Llera-Moya, and et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
37. A. Rohatgi, A. Khera, J.D. Berry, and et al. HDL cholesterol efflux capacity and incident cardiovascular events N Engl J Med 371 2014 2383 2393
38. X.M. Li, W.H. Tang, M.K. Mosior, and et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks Arterioscler Thromb Vasc Biol 33 2013 1696 1705
39. D.J. Rader, G. Ruotolo, J.P. Kane, and et al. Abstract 12252: Effects of the Cholesteryl Ester Transfer Protein Inhibitor, Evacetrapib, Administered as Monotherapy or in Combination With Statins on Cholesterol Efflux and HDL Particles in Patients With Dyslipidemia Circulation 130 2014 A12252
40. J.P. Kane, and M.J. Malloy Prebeta-1 HDL and coronary heart disease Curr Opin Lipidol 23 2012 367 371
41. A. Kontush, S. Chantepie, and M.J. Chapman Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress Arterioscler Thromb Vasc Biol 23 2003 1881 1888
42. T. Vaisar, S. Pennathur, P.S. Green, and et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 2007 746 756